Should Value Investors Pick Tenet Healthcare (THC) Stock? – Yahoo Finance

plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and Momentum Score of A. This gives THT a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter has seen five upward revisions in the past sixty days compared to three downward revisions, while the current year estimate has also seen five upward revisions compared to three downward revisions in the same time period.

As a result, the current quarter consensus estimate rose 31.8% in the past two months, whereas the current year estimate rose 0.85%. You can see the consensus estimate trend and recent price action for the stock in the chart below:” data-reactid=”47″>
 
Broad Value Outlook

In aggregate, Tenet Healthcare currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Tenet Healthcare a solid choice for value investors.

For example, the PEG ratio for Tenet Healthcare is just 0.55, a level that is lower than the industry average of 1.06. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, P/CF ratio (another great indicator of value) comes in at 2, which is marginally better than the industry average of 4.97. Clearly, THT is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Tenet Healthcare might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and Momentum Score of A. This gives THT a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter has seen five upward revisions in the past sixty days compared to three downward revisions, while the current year estimate has also seen five upward revisions compared to three downward revisions in the same time period.

As a result, the current quarter consensus estimate rose 31.8% in the past two months, whereas the current year estimate rose 0.85%. You can see the consensus estimate trend and recent price action for the stock in the chart below: